To apply for the Anthem Biosciences IPO, investors need to log in to their trading account through a registered broker’s online platform. Within the IPO section, select “Anthem Biosciences IPO” from the active listings. Choose the number of lots, keeping in mind the minimum lot size of 26 shares, and enter the desired bid price within the specified price band of ₹540 to ₹570 per share. Enter your UPI ID for payment authorisation and ensure sufficient funds are available in your linked bank account. Carefully review all details and submit the application. It is important to approve the UPI mandate before 5 PM on July 16, 2025, to complete the process successfully.
For complete details on this public offering, visit the Anthem Biosciences IPO page on Bajaj Broking’s website.
Anthem Biosciences IPO Application Process
The Anthem Biosciences IPO application process can be completed online through your trading platform. Below is a step-by-step guide to applying for the IPO:
Step 1: Login to Your Trading Platform
Access your trading account using Bajaj Broking’s app or website.
Step 2: Navigate to the IPO Section
Go to the IPO section to view active IPO listings.
Step 3: Select the Open IPO and Click Apply
Locate Anthem Biosciences IPO in the list of available IPOs and click the ‘Apply’ button.
Step 4: Enter the Quantity of Shares You Wish to Apply For
Specify the number of shares (minimum lot size: 26 shares) within the price band of ₹540 to ₹570 per share.
Step 5: Provide Your UPI ID
Enter your UPI ID for payment authorization and ensure sufficient funds in your bank account.
Step 6: Confirm the Application
Review your application details and confirm the UPI mandate before 5 PM on the last application day.
Step 7: Complete the Process and Wait for Allotment
Submit the application and monitor the allotment status to check if shares have been allocated to you.
Additional Read: Anthem Biosciences IPO Investment Guide: Objectives & Opportunities
About Anthem Biosciences IPO: Overview and Key Facts
Anthem Biosciences Limited, launched in 2006, offers integrated services in contract research, development, and manufacturing (CRDMO). Its operations span from early-stage drug discovery and development to commercial manufacturing. The company serves a global client base, including both emerging biotechnology firms and established pharmaceutical companies. Its core product lineup focuses on fermentation-derived active pharmaceutical ingredients (APIs), such as enzymes, peptides, vitamin analogues, probiotics, and biosimilars. Anthem’s platform covers multiple therapeutic modalities—RNA interference (RNAi), antibody-drug conjugates (ADC), peptides, lipids, and oligonucleotides—supported by four manufacturing technologies including fermentation and flow chemistry.
As of late September 2024, Anthem Biosciences was handling nearly two hundred projects across discovery, early and late-stage development, and commercial phases. The initiative includes support for ten commercial molecules, spanning discovery to production. The company’s global footprint extends across more than 44 countries, with clients in North America, Europe, Japan, and beyond. Anthem holds patents in India and abroad, and has filed additional patent applications in areas such as glycolipid synthesis and GLP‑1 analogues, indicating ongoing investment in proprietary processes and innovation.
The Anthem Biosciences IPO will be open for subscription from July 14 to July 16, 2025, with a price range set between ₹540 and ₹570 per share. Investors may apply in multiples of 26 shares per lot; retail applications start from one lot. The IPO involves the offer for sale of nearly 596 million shares aggregating to approximately ₹3,395 crore, and will be listed on both BSE and NSE. The registrar handling the issue is Kfin Technologies Limited, with JM Financial as the lead manager. Key dates include allotment on July 17, initiation of refunds and share credits on July 18, and tentative listing on July 21, pending regulatory clearance.
To check your application status, visit the Anthem Biosciences IPO Allotment Status page on Bajaj Broking’s website.